Group 1 - The company plans to globally offer 26.54 million shares, with 2.65 million shares available in Hong Kong and 23.89 million shares for international sale, along with an over-allotment option of 3.98 million shares [1] - The subscription period is set from December 15 to December 18, with a maximum offer price of HKD 22.68 per share and an entry fee of approximately HKD 4,581.75 for 200 shares [1] - The total expected fundraising amount is HKD 602 million, with a net amount of HKD 513 million, aimed at enhancing brand awareness, user engagement, and partnerships, as well as improving technology capabilities in AI and big data [1] Group 2 - The company has introduced cornerstone investors, including Guangdong Hengqin Guangdong-Macao Deep Cooperation Zone Aoqin Harmony Investment Partnership, which will subscribe to approximately 4.80 million shares at the offer price [1] - The company is expected to be listed on the main board by December 23, 2025, with China International Capital Corporation Hong Kong Securities Limited and China Merchants Securities (Hong Kong) Co., Limited acting as joint sponsors [1] - The company reported net profits of CNY 73.645 million, CNY 10.398 million, and CNY 86.045 million for the fiscal years 2023, 2024, and the first half of 2025, reflecting year-on-year changes of 3,673.27%, -85.88%, and 437.92% respectively [2]
轻松健康拟全球发售2654.00万股 12月15日起招股